Inhibition of Anthrax Lethal Toxin-Induced Cytolysis of RAW264.7 Cells by Celastrol

Sarah Chapelsky, Sarah Batty, Mia Frost, Jeremy Mogridge*

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Background. Bacillus anthracis is the bacterium responsible for causing anthrax. The ability of B. anthracis to cause disease is dependent on a secreted virulence factor, lethal toxin, that promotes survival of the bacteria in the host by impairing the immune response. A well-studied effect of lethal toxin is the killing of macrophages, although the molecular mechanisms involved have not been fully characterized. Methodology/Principal Findings. Here, we demonstrate that celastrol, a quinone methide triterpene derived from a plant extract used in herbal medicine, inhibits lethal toxin-induced death of RAW264.7 murine macrophages. Celastrol did not prevent cleavage of mitogen activated protein kinase kinase kinase 1, a cytosolic target of the toxin, indicating that it did not inhibit the uptake or catalytic activity of lethal toxin. Surprisingly, celastrol conferred almost complete protection when it was added up to 1.5 h after intoxication, indicating that it could rescue cells in the late stages of intoxication. Since the activity of the proteasome has been implicated in intoxication using other pharmacological agents, we tested whether celastrol blocked proteasome activity. We found that celastrol inhibited the proteasome-dependent degradation of proteins in RAW264.7 cells, but only slightly inhibited proteasome-mediated cleavage of fluorogenic substrates in vitro. Furthermore, celastrol blocked stimulation of IL-18 processing, indicating that celastrol acted upstream of inflammasome activation. Conclusions/Significance. This work identifies celastrol as an inhibitor of lethal toxin-mediated macrophage lysis and suggests an inhibitory mechanism involving inhibition of the proteasome pathway.

INTRODUCTION

Anthrax lethal toxin (LeTx) comprises two proteins that are secreted separately by Bacillus anthracis and that form complexes on the surface of mammalian cells [1]. The protective antigen (PA) component of the toxin binds host cellular receptors and is proteolytically activated by furin-like proteases. The proteolytic activation of PA causes dissociation of an amino-terminal fragment of the protein, which allows the homo-oligomerization of the receptor-bound carboxy-terminal fragment, PA63. Heptamers of PA63 bind the second toxin component, lethal factor (LF) [2–4]. These toxin complexes are internalized by receptor-mediated endocytosis and LF is delivered to the cytosol after translocating through a membrane-spanning pore formed by the heptamer [5,6]. LF disrupts signaling pathways by cleaving members of the mitogen activated protein kinase kinase (MAPKK) family, thereby interfering with normal cellular functions [7].

The contribution of LeTx to anthrax pathogenesis is complex and is likely mediated through several different mechanisms and cell types [8]. The relative importance to pathogenesis of each of the effects of intoxication is unknown and may differ depending on the site of infection and the infection model. Numerous reports support the notion that the toxin disrupts the immune system, which would aid bacterial survival and support disease progression. LeTx inhibits cytokine expression in T cells, dendritic cells, macrophages, and endothelial cells [9–13]. LeTx inhibits production of Type IIa phospholipase A2 by macrophages [14], differentiation of monocytes into macrophages [15], production of immunoglobulin by B cells [16], production of superoxide by neutrophils [17], and impairs neutrophil motility [18]. In addition, LeTx causes cytotoxicity in macrophages, dendritic cells and certain types of endothelial cells [19–21].

Macrophages seem to both promote and control anthrax infections. Phagocytosis of B. anthracis spores by macrophages promotes their germination [22]; but macrophages reduce susceptibility of mice to anthrax infections [23], probably through direct killing of extracellular bacilli. Intoxication of macrophages influences both of these interactions: first, by facilitating the escape of bacilli that have germinated from phagocytosed spores [24], and second, by killing macrophages that can destroy the bacilli.

Macrophages derived from some strains of mice undergo cytosis after being exposed to LeTx and it was discovered recently that susceptibility to LeTx-induced cytosis is determined by the allele of the Nalp1b gene [25]. Human NALP1 is a component of the inflammasome, which is a complex consisting of NALP1, ASC, caspase-1 and caspase-5 [26]. Assembly of the inflammasome activates caspase-1 and caspase-5, leading to the processing of pro-inflammatory cytokines IL-1β and IL-18. Activation of caspase-1 by murine Nalp1b mediates macrophage cytosis through the mitochondrial proteins Bnip3 and Bnip3L [25,27], but it is unclear why the inflammasome is activated by the action of LeTx. LeTx-mediated cytosis of the susceptible macrophage cell line J774.A.1 is accompanied by a proteasome-dependent loss of mitochondrial membrane potential and membrane swelling [28–30]. Subsequent to impairment of...
mitochondria, the plasma membrane is compromised, ATP levels drop, and cytotoxicity occurs [29].

Celastrol is a small molecule derived from the plant *Tripterygium wilfordii* that has been shown to have cytoprotective properties [31,32], so we sought to determine whether celastrol could protect macrophages from LTx-induced cytotoxicity. In this study, we demonstrated that celastrol inhibited LeTx-mediated death of the murine macrophage cell line RAW264.7. Celastrol did not inhibit cleavage of MAPKK1, indicating that it did not block toxin internalization or the proteolytic activity of LF. Furthermore, celastrol was able to protect cells that had been pre-exposed to the toxin, suggesting that it inhibited a late stage of intoxication. We found that celastrol blocked proteasome-mediated destruction of ubiquitylated proteins and prevented LeTx-stimulated processing of IL-18, suggesting that the cytoprotective effects of celastrol are a result of its ability to inhibit the proteasome pathway, thereby preventing inflammusome activation.

**MATERIALS AND METHODS**

**Reagents**

Celastrol, rabbit 20S proteasome, and Z-Leu-Leu-Glu-7-amido-4-methylcoumarin (Z-LL-AMC) were obtained from Calbiochem. MG132, lipopolysaccharide (cat. # L2630), 7-amino-4-methylcoumarin (AMC), and N-sucinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (Suc-LL-AMC) were obtained from Sigma. Glutathione-agarose immobilised GST-S5a, purified 26S proteasome, ATP (cat. # EW9805), t-butoxycarbonyl-Leu-Arg-Arg-7-amido-4-methylcoumarin (Boc-LRR-AMC), and acetyl-L-norleucyl-yl-prolyl-L-norleucyl-L-aspartyl-methylcoumarylumide (Ac-nLPhLD-AMC) were obtained from Biomol International. PA and LF were purified as described previously [15].

**Cell culture and cytotoxicity assays**

RAW 264.7 cells were maintained in RPMI supplemented with 5% fetal bovine serum and 1% penicillin-streptomycin. For cell culture and cytotoxicity assays, cells were seeded into tissue culture-treated 96-well plates (Corning) at a density of 10^5 viable cells per well and incubated overnight at 37°C and 5% CO_2_. Cells treated with LeTx were exposed to 10^-8 M PA and 5×10^-10 M LF. Cell viability was assessed using the CellTiter 96 Aqueous One Solution Cell Proliferation assay (Promega), as per manufacturer's instructions.

**Western blot assays**

Cells were harvested in 1× Cell Lysis Buffer (Cell Signaling Technologies) containing 1 mM phenylmethylsulfonyl fluoride and were sonicated (3×15 seconds). Lysates were cleared by centrifugation; equal amounts of protein were separated on an SDS-polyacrylamide gel and transferred to nitrocellulose. Membranes were blocked in 0.1% Tween-20 TBS (100 mM Tris-HCl pH 8.0, 0.9% NaCl) containing 5% skim milk powder, and were probed with primary antibodies. Antibodies raised against IL-18 (BioVision), IgBz (Santa Cruz Technologies), ubiquitin (Dako), z-tubulin (Sigma), and the N-terminus of MAPKK1 (Upstate Technologies) were used according to manufacturer's instructions.

**GST-S5a agarose pulldown**

Cell lysates were prepared from RAW264.7 cells that had been treated with 10 μM MG132 for 1 h. GST or GST-S5a coupled to sepharose (20 μL of 0.5 mg protein/mL resin) was combined with 50 μg lysate in 250 μL of Cell Lysis Buffer (Cell Signaling Technologies) containing 5% glycerol. This mixture was rotated at 4°C for 2 h, either in the presence or absence of 10 μM celastrol. Beads were washed three times with lysis buffer, and proteins were eluted with SDS loading dye. Western blot analysis was performed using anti-ubiquitin antibody.

**20S proteasome proteolytic activity**

Reactions were carried out in 50 mM Tris-HCl pH 8.0 containing 0.03% SDS in a volume of 200 μL. Suc-LLVY-AMC was used at a final concentration of 30 μM, and 0.4 μg of 20S proteasome was used per reaction. A constant concentration of 0.4% DMSO was maintained in all wells. Fluorescence (excitation 380 nm, emission 460 nm) was measured every 30 s for 40 min. The slope of the initial linear portion of the curve (over a 15 min interval) was determined using Prism 3.0 (GraphPad Software Inc.). Standard curves were generated using AMC in the presence of the compounds tested, and the amount of AMC liberated per unit time was calculated.

**26S proteasome proteolytic activity**

Reactions were carried out in 50 mM Tris-HCl pH 7.5 containing 40 mM KCl, 5 mM magnesium chloride, 0.5 mM ATP, 1 mM DTT, and 0.5 mg/mL BSA in a volume of 200 μL. Suc-LLVY-AMC, Ac-nLPhLD-AMC, and Boc-LRR-AMC were used at a final concentration of 100 μM. To measure cleavage of Suc-LLVY-AMC, 0.2 μg of 26S proteasome was used per reaction. For the other substrates, 0.75 μg of 26S proteasome was used. A constant concentration of 1% DMSO was maintained in all wells. Fluorescence (excitation 380 nm, emission 460 nm) was measured every 30 s for 2 h. The slope of the initial linear portion of the curve (over a 15 min interval) was determined using Prism 3.0 (GraphPad Software Inc.). Standard curves were generated using AMC in the presence of the compounds tested, and the amount of AMC liberated per unit time was calculated.

**Proteasome proteolytic activity of RAW264.7 cell lysates**

RAW264.7 cells were washed twice with PBS and suspended in reaction buffer (50 mM Tris-HCl pH 7.5 containing 250 mM sucrose, 5 mM magnesium chloride, 2 mM ATP, 1 mM DTT, and 0.5 mM EDTA). Cells were sonicated for 15 s and lysates were cleared by centrifugation. Reactions were performed in a volume of 200 μL using a final concentration of 100 μM Suc-LLVY-AMC and 25 μg protein lysate per reaction. A constant concentration of 1% DMSO was maintained in all wells. Fluorescence was measured and data was analyzed as described above for the 26S proteasome assay.

**RESULTS AND DISCUSSION**

To determine whether celastrol can protect RAW264.7 cells from LeTx-induced death, we treated cells for 4 h with LeTx in the absence or presence of celastrol. Cell viability was estimated using the MTS assay, which measures the reduction of a tetrazolium salt to formazan by metabolically active cells. Treatment of cells with LeTx (10^-8 M PA and 5×10^-10 M LF) alone reduced metabolic activity, whereas treatment with 3 μM celastrol alone had little effect (Fig. 1A). Cells that were co-treated with LeTx and celastrol exhibited metabolic activity similar to untreated cells. Celastrol also protected the J774A.1 murine macrophage cell line from intoxication (data not shown), demonstrating that this activity is not restricted to RAW264.7 cells.

We next sought to determine whether celastrol inhibited either toxin internalization or the enzymatic activity of LF by monitoring...
cleavage of MAPKK1, a cytosolic target of LF. Cells were treated with LeTx, celastrol, or both for 1 h. Cellular extracts were prepared and examined by Western blotting using an antibody that recognizes the amino terminus of MAPKK1; LF cleaves an amino-terminal segment from MAPKK1, so this antibody does not detect the cleaved protein. A reduced amount of full-length MAPKK1 was observed in cells treated with LeTx compared to untreated cells (Fig. 1B). Celastrol did not prevent cleavage of MAPKK1 by LeTx, however, indicating that celastrol did not inhibit the delivery of LF to the cytosol or the proteolytic activity of this enzyme.

Since celastrol did not inhibit substrate cleavage by LF, this result indicated that this compound might block a late step in intoxication. To address this possibility, we performed a time-course assay to determine how late during intoxication celastrol could confer protection (Figs. 1C, D). Celastrol was added to cells at different times after toxin addition and the MTS assay was performed 4 h after the toxin was added. In parallel, cells were treated for different amounts of time with LeTx alone to assess the metabolic activity of cells at the times of celastrol addition. A slight reduction in metabolic activity was observed after 1 h of toxin treatment, which became more pronounced at 1.5 h and 2 h (Fig. 1C). By 3 h of toxin treatment, an almost maximal reduction in metabolic activity was observed. Remarkably, 10 μM celastrol was able to completely protect cells that had been exposed to LeTx for 1.5 h and stopped further loss in metabolic activity in cells exposed to toxin for 2 h (Figs. 1C, D). These results indicate that celastrol protects cells by inhibiting a process that occurs late in intoxication.

Since celastrol has been reported to inhibit proteasome activity in prostate cancer cell lines [33], we assessed whether celastrol might inhibit the proteasome-dependent degradation of proteins in RAW264.7 cells. To test this idea, we treated RAW264.7 cells with lipopolysaccharide (LPS) and probed cell lysates for IκB-α, which is degraded by the proteasome in cells that have been stimulated by LPS. Western blotting indicated that LPS treatment...
led to the degradation of IκB-α and that this could be inhibited by the proteasome inhibitor, MG132 (Fig. 2A). Celastrol was also able to inhibit the degradation of IκB-α at a concentration that protected RAW264.7 cells from LeTx. As an additional test of whether celastrol inhibited the degradation of ubiquitylated proteins, we treated cells with either MG132 or celastrol and examined cell lysates for ubiquitylated proteins by Western blotting with an anti-ubiquitin antibody (Fig. 2B). We observed that treatment of cells with either MG132 or celastrol led to the accumulation of ubiquitylated proteins, suggesting that celastrol inhibits a step in the proteasome pathway. Interestingly, celastrol treatment resulted in the accumulation of more ubiquitylated proteins than did MG132. Because MG132 is a potent inhibitor of the proteasome, we speculated that the ability of celastrol to cause a greater accumulation of ubiquitylated proteins than MG132 might be a result of an additional activity of celastrol that induces the accumulation of misfolded proteins. Indeed, celastrol has been reported to inhibit HSP90 [34]; inhibition of HSP90 would cause an accumulation of misfolded proteins that would subsequently be ubiquitylated. To test this hypothesis, we treated cells with either celastrol or MG132 in the presence or absence of the HSP90 inhibitor geldanamycin (Fig. 2C). The combination of geldanamycin and celastrol resulted in a level of ubiquitylated proteins similar to that in cells treated with celastrol alone. In contrast, geldanamycin increased the level of ubiquitylated proteins in cells treated with MG132. These results indicate that the higher level of ubiquitylated proteins in celastrol-treated cells compared to MG132-treated cells results from the ability of celastrol to induce protein misfolding (through the inhibition of HSP90) in addition to inhibiting proteasome-mediated degradation of proteins.

We next assessed whether a threshold of total cellular ubiquitylated proteins was required to protect RAW264.7 cells from LeTx. Cells were treated with LeTx in the presence of various concentrations of either celastrol or MG132 and the cells were assessed for viability. Celastrol protected cells at a concentration of 3 μM, but not at 1 μM; MG132 protected cells at 1 μM, but not at 0.3 μM (Fig. 2D). Because there are slightly more ubiquitylated proteins in cells treated with 1 μM MG132 (Fig. 2B), we conclude that there is not a direct correlation between the bulk accumulation of ubiquitylated proteins and the protection of cells from intoxication. It is possible that inhibiting the degradation of only one or a few ubiquitylated proteins prevents LeTx-mediated cytolysis.

Ubistatins are compounds that block proteasome-mediated protein degradation by binding ubiquitin chains, thereby inhibiting the interaction between ubiquitylated proteins and the proteasome [35]. To determine if celastrol functions similarly, we assessed whether celastrol blocked the ability of the ubiquitin receptor S5a to bind ubiquitylated proteins. Glutathione-S-transferase (GST) or a GST-S5a fusion protein was attached to glutathione-sepharose beads and the beads were mixed with RAW264.7 cellular lysates and then centrifuged to isolate associated proteins. The associated proteins were electrophoresed on denaturing polyacrylamide gels and then probed with anti-ubiquitin antibody (Fig. 3). GST-S5a precipitated ubiquitylated proteins shown. (C) RAW264.7 cells were treated with 10 μM celastrol, 10 μM MG132 and/or 10 μM geldanamycin for 1 h. Cellular lysates were prepared and probed with anti-ubiquitin or anti-α-tubulin. A representative result of three independent experiments is shown. (D) RAW264.7 cells were treated with various concentrations of celastrol or MG132 in the presence (black bars) or absence (white bars) of LeTx for 4 h. Cell viability was assessed using the MTS assay. The means of three experiments ± SEM are reported. doi:10.1371/journal.pone.0001421.g002

Figure 2. Celastrol inhibits the proteasome-dependent degradation of proteins. (A) RAW264.7 cells were treated with 3 μM celastrol or 10 μM MG132 (or DMSO vehicle) for 30 min, followed by a 10 min treatment with 1 μg/mL LPS. Cellular lysates were prepared and probed for IκB-α or α-tubulin by Western blotting. A representative result of three independent experiments is shown. (B) RAW264.7 cells were treated with indicated concentrations of celastrol or MG132 for 1 h. Cellular lysates were prepared and probed with anti-ubiquitin or anti-α-tubulin. A representative result of three independent experiments is shown. (C) RAW264.7 cells were treated with 10 μM celastrol, 10 μM MG132 and/or 10 μM geldanamycin for 1 h. Cellular lysates were prepared and probed with anti-ubiquitin or anti-α-tubulin. A representative result of three independent experiments is shown. (D) RAW264.7 cells were treated with various concentrations of celastrol or MG132 in the presence (black bars) or absence (white bars) of LeTx for 4 h. Cell viability was assessed using the MTS assay. The means of three experiments ± SEM are reported. doi:10.1371/journal.pone.0001421.g002
proteins, whereas GST did not. Celastrol did not prevent GST-S5a from binding ubiquitylated proteins, suggesting that celastrol does not interfere with the binding of ubiquitin chains to the proteasome.

We next assessed whether celastrol inhibited the proteolytic activity of the proteasome. The 26S proteasome is a large multisubunit complex consisting of a 20S barrel-shaped core complex and two 19S regulatory complexes [36]. The regulatory complexes ensure that only ubiquitylated proteins access the inside of the barrel where the proteolytic sites reside. The proteasome exhibits three distinct proteolytic activities, chymotrypsin-like, trypsin-like, and caspase-like, which can be assayed individually using fluorogenic substrates [37]. The chymotrypsin-like site is thought to be the most important of the three, although the trypsin-like and caspase-like activities must also be inhibited to reduce the degradation of most proteins by 50% [37]. We mixed purified 26S proteasome with the fluorogenic substrate N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (Suc-LLVY-AMC) to measure chymotrypsin-like activity; t-butoxycarbonyl-Leu-Arg-Arg-7-amido-4-methylcoumarin (Boc-LRR-AMC) to measure trypsin-like activity; or acetyl-L-norleucyl-L-prolyl-L-norleucyl-L-aspartyl-methylcoumarylamide (Ac-nLPnLD-AMC) to measure caspase-like activity. Whereas MG132 inhibited cleavage of the three substrates, neither 3 μM nor 10 μM celastrol was able to inhibit cleavage of the substrates by the 26S proteasome (Fig. 4A). Celastrol showed some inhibitory activity against the chymotryptic activity of the 20S proteasome at 10 μM, but not at 3 μM (Fig. 4B), a concentration that was sufficient to cause the accumulation of ubiquitylated proteins in vivo (Fig. 2B). To test further whether celastrol inhibited proteasome activity, we incubated RAW264.7 cell lysates with Suc-LLVY-AMC. MG132 reduced the rate of cleavage of this substrate, but celastrol exhibited little inhibitory activity (Fig. 4C).

Since it has been reported previously that inhibition of proteasome activity prevents activation of the Nalp1b inflammasome [38,39], we sought to determine whether celastrol inhibits processing of IL-18 by the Nalp1b inflammasome. RAW264.7 cells were incubated with LeTx in the absence or presence of celastrol for 2 h and cellular lysates and supernatants were
subjected to Western blotting using an antibody raised against IL-18. The 18 kDa mature form of IL-18 was observed in lysates derived from cells treated with LeTx and a reduced amount was present in lysates derived from cells treated with both LeTx and celastrol; no IL-18 was detected in the cell supernatants in these conditions (Fig. 5). J774A.1 cells that were treated with LeTx had a reduced amount of the 24 kDa form of IL-18 in cell lysates; the processed form was observed in the supernatants. The stimulation of IL-18 processing by LeTx was reduced in cells that were co-treated with celastrol (Fig. 5). These results are consistent with celastrol inhibiting an intoxication step upstream of Nalp1b inflammasome activation.

In summary, we have demonstrated that celastrol inhibits LeTx-induced cytolysis of RAW264.7 murine macrophage cells. The concentrations required to protect cells (Fig. 2D) were similar to the concentrations that led to the accumulation of ubiquitylated proteins (Fig. 2B). Comparison of celastrol with MG132, however, suggested that protection from cytolysis did not correlate with a threshold level of total ubiquitylated proteins – this suggests that the degradation of a relatively small subset of ubiquitylated proteins may be required for cytolysis. The spectrum of ubiquitylated proteins likely differs between celastrol-treated and MG132-treated cells because celastrol inhibits HSP90, which helps to fold a variety of proteins, in addition to inhibiting proteasome-mediated degradation of proteins. Inhibition of HSP90 by geldanamycin did not protect cells from LeTx (data not shown).

Proteasome activity has previously been implicated in LeTx-mediated cytolysis by structurally unrelated proteasome inhibitors [28]. Recently, a report suggested that celastrol inhibits 20S proteasome activity [33]. Using a fluorogenic substrate, we did detect a slight decrease in 20S proteasome activity in vitro, but not in 26S proteasome activity – although 20S proteasome does exist in cells, it is thought that the 26S proteasome is responsible for the degradation of ubiquitylated proteins [37]. Thus, we believe that celastrol either inhibits the proteolytic activity of the 26S proteasome only in intact cells, or it inhibits another step in the ubiquitin-proteasome pathway. Inhibition of the ubiquitin-proteasome pathway is a potential therapeutic strategy for the treatment of cancer and neurodegenerative diseases [40], so it will be important to characterize further how celastrol inhibits this pathway and to determine whether it could be used to treat anthrax.

ACKNOWLEDGMENTS

Author Contributions
Conceived and designed the experiments: JM SC SB MF. Performed the experiments: SC SB MF. Analyzed the data: JM SC SB MF. Wrote the paper: JM.

REFERENCES

1. Collier RJ, Young JA (2003) Anthrax toxin. Annu Rev Cell Dev Biol 19: 45–70.
2. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G (1992) Human furin is a calcium-dependent serine endopeptidase that recognizes the sequence Arg-N-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 267: 16396–16402.
3. Milne JC, Furlong D, Hanna PG, Wall JS, Collier RJ (1994) Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J Biol Chem 269: 20607–20612.
4. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ (2002) The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci U S A 99: 7045–7048.
5. Abraimb L, Liu S, Crosson P, Leppla SH, van der Goot FG (2003) Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol 160: 321–328.
6. Zhang S, Finkelstein A, Collier RJ (2004) Evidence that translocation of anthrax toxin’s lethal factor is initiated by entry of its N terminus into the protective antigen channel. Proc Natl Acad Sci U S A 101: 16756–16761.
7. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. (1998) Proteolytic inactivation of MAP kinase kinase by anthrax lethal factor. Science 280: 734–737.
8. Banks DJ, Ward SC, Bradley KA (2006) New insights into the functions of anthrax toxin. Expert Rev Mol Med 8: 1–18.
9. Fang H, Cordoba-Rodriguez R, Lankford CS, Frucht DM (2005) Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells. J Immunol 174: 4966–4971.
10. Paccani SR, Tonello F, Gattioni R, Natale M, Muraro L, et al. (2005) Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med 201: 325–331.
11. Agrawal A, Langappa J, Leppla SH, Agrawal S, Jabbar A, et al. (2003) Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329–334.
12. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN-gamma-induced release of NO and TNF-alpha. FEMS Lett 182: 199–204.
13. Batty S, Chow EM, Kassam A, Der SD, Mogridge J (2006) Inhibition of mitogen-activated protein kinase signalling by Bacillus anthracis lethal toxin causes destabilization of interleukin-8 mRNA. Cell Microbiol 8: 130–138.
14. Gimenez AP, Wu ZY, Paya M, Delclaux C, Touqui L, et al. (2004) High bactericidal efficiency of type IIia phospholipase A2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin. J Immunol 173: 521–530.
15. Kassam A, Der SD, Mogridge J (2005) Differentiation of human monocytic cell lines confers susceptibility to Bacillus anthracis lethal toxin. Cell Microbiol 7: 311–292.
16. Fang H, Xu L, Chen TY, Cyn JM, Frucht DM (2006) Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J Immunol 176: 6155–6161.
17. Crawford MA, Ayloff CV, Bourdeau RW, Bokoch GM (2006) Bacillus anthracis Toxin Inhibit Human Neutrophil NADPH Oxidase Activity. J Immunol 176: 7557–7563.
18. During RL, Li W, Hao B, Koenig JM, Stephens DS, et al. (2005) Anthrax lethal toxin paralyzes neutrophil actin-based motility. J Infect Dis 192: 837–845.
19. Friedlander AM (1986) Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 261: 7123–7126.
20. Allieche A, Serfas ER, Muhlhauser SM, Porcelli SA, Brojatsch J (2005) Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog 1: e19.
21. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, et al. (2005) Braf status and mitogen-activated protein/extracellular signal-regulated kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 4: 1303–1310.
22. Guidi-Rontani C, Weber-Leyv Y, Labuyere E, Mock M (1999) Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 31: 9–17.
23. Cote CK, Van Rooijen N, Welkos SL (2006) Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect Immun 74: 469–480.
24. Banks DJ, Barnajian M, Maldonado-Arocho IJ, Sanchez AM, Bradley KA (2005) Anthrax toxin receptor 2 mediates Bacillus anthracis killing of macrophages following spore challenge. Cell Microbiol 7: 1173–1185.
25. Boyden ED, Dietrich WF (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38: 240–244.
26. Tschopp J, Maritomin F, Burni K (2003) NALPs, a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 4: 95–104.
27. Ha SD, Ng D, Lamothe J, Valvano MA, Han J, et al. (2007) Mitochondrial proteins Bnip3 and Bnip3L are involved in anthrax lethal toxin-induced macrophage cell death. J Biol Chem 282: 26273–26283.
28. Tang G, Leppla SH (1999) Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect Immun 67: 3055–3060.
29. Ailleche A, Squires RC, Muehlbauer SM, Lisanti MP, Brojatsch J (2006) Mitochondrial impairment is a critical event in anthrax lethal toxin-induced cytosis of murine macrophages. Cell Cycle 5: 100–106.
30. Salles II, Tucker AF, Voth DE, Ballard JD (2003) Toxin-induced resistance in Bacillus anthracis lethal toxin-treated macrophages. Proc Natl Acad Sci U S A 100: 12426–12431.
31. Westerheide SD, Boman JD, Mbadugha BN, Kawahara TL, Matsumoto G, et al. (2004) Celastrol as inducers of the heat shock response and cytoprotection. J Biol Chem 279: 56053–56060.
32. Cleren C, Calinskas NY, Chen J, Beal MF (2005) Celastrol protects against MPTP- and 3-nitropipionic acid-induced neurotoxicity. J Neurochem 94: 995–1004.